IMMVAC, Inc. (Columbia, MO)

IMMVAC, Inc.(www.immvac.com), whose assets exceed $50 million and annual sales revenues exceed $37.5 million per annum, was founded and incorporated in 1984 by its two principal owners, Dr. Ron Sprouse (former MU Professor of Pathology in the School of Medicine) and his wife, Dorothy; with Dr. Harold Garner (MU Professor Emeritus of Veterinary Medicine), his wife, Patsy, with one other investor. IMMVAC's product portfolio includes a line of broad spectrum bacterins that protect animals against gram-negative bacterial insults. The products are marketed and sold into the production and companion animal health market sector, including dairy, beef, pigs, dogs, cats, and horses. In addition to the bacterin technology, IMMVAC also markets a line of viral vaccines into the same target markets.

IMMVAC's products are based on the following exclusively owned core technologies: 1) its patented, genetically engineered, gram negative mutant Bacterin, Re-17 (Re Chemotype), which is comprised of the "universal core antigen" common to all gram-negative bacteria, and 2) its patented, immunopotentiator, E3, which stimulates T and B-lymphocytes, thereby enhancing overall immunity to disease.

IMMVAC manufactures their products at a USDA licensed plant facility located in Columbia, MO. Production facilities utilize good manufacturing practices (GMP) and modern bio-reactor technology, with existing capacity for 35-40 million doses annually; and approximately 10,000 liters of serum annually, with existing capacity for in excess of 20,000 liters annually. IMMVAC employs 40 people at its Columbia, MO facility.

---

Megan Health, Inc. (origin in St. Louis, MO)

Megan Health Inc. was founded by Washington University professor Roy Curtiss III in 1993, to develop vaccines to combat diseases in both animals and humans. Dr. Brian Clevinger was CEO from Megan's inception in 1993 until its acquisition in 2000. The company brought its first product, a chicken salmonella vaccine, to market in 1999. It was bought by AVANT Immunotherapeutics, Inc. (www.avantimmune.com). The start-up was funded by Upjohn Co., the major pharmaceutical manufacturer, and A/W Company, a joint venture of Washington University and Moshe Alafi, a California-based venture capitalist that tries to turn Washington University research into commercial products.

From 1987 to 1993, Dr. Clevinger was President and CEO of A/W Company. In this capacity, he worked with WU researchers, including Dr. Curtiss, to identify projects with high commercial potential, evaluated markets, competition and other business factors and presented his analysis to Alafi Capital for seed funding. Once a funding decision was made, he acted an interim manager, conducted the search for a permanent management team, and served as a Board member.
Prior to joining A/W Company, Dr. Clevinger held a tenured faculty position at Washington University since 1980. He earned his Ph.D. in immunology from Indiana University and was NIH post-doctoral fellow at Washington University. He is currently a managing director with Prolog Ventures (www.prologventures.com) in St. Louis, an early-stage venture capital firm focusing on life science start-ups in the Missouri region. Dr. Clevinger's investment activities at Prolog emphasize biotechnology and medical devices. He has been involved in the funding of sixteen biomedical start-ups in the St. Louis region and has been an advisor to many more.

---

APT Therapeutics™ (www.apttherapeutics.com) , currently located in the Nidus Center for Scientific Enterprise (www.niduscenter.com) in St. Louis, was founded in December 2001. In April, 2002 the company secured $1.6 million in venture financing from Prolog Ventures (St. Louis) and CID Equity Partners of Indianapolis (www.cidequity.com). The founders consisted of three former Monsanto and university scientists who had developed a highly innovative drug development platform capable of accelerating the development of proteins and small molecule therapeutics. APT used this platform to develop several anti-thrombotic therapeutic proteins to be used in stroke, percutaneous coronary intervention and acute coronary syndrome. These proteins were developed by improving a protein that was extensively tested by a large biotech company and found to be too expensive to produce and not sufficiently efficacious. The scientists at APT used their drug design platform to "fix" the protein which has been confirmed in animal trials. APT is currently seeking to raise an additional round of financing to fund preclinical work leading to at least one Investigational New Drug application (IND) with the FDA.

Dr. Ridong Chen is the founder of APT Therapeutics™ and the inventor of APT's key technologies. He has been Chief Science Officer since APT's incorporation. Dr. Chen was instrumental in defining the business vision, assembling a top-tier technical team and raising Series A capital for the company. Dr. Chen previously built and led the protein engineering team at Monsanto/Pharmacia for nutraceutical development. Dr. Brian Clevinger serves as member of the APT board of directors.

---

Chlorogen, Inc. (St. Louis, MO)

Chlorogen, Inc. (www.chlorogen.com) was founded in May 2003 and is located in the Nidus Center for Scientific Enterprise, St. Louis. The founder of Chlorogen, Dr. Henry Daniell is a University of Central Florida professor who developed a proprietary method of expressing genes in the chloroplast of tobacco and other plants such that proteins are produced in extraordinary amounts. His lab at UCF (http://pegasus.cc.ucf.edu/%7Edaniell) continues to develop products which will become part of Chlorogen's intellectual property portfolio. Former Monsanto, Mycogen, and CropTech executives form the management team. Dr. Brian Clevinger, of Prolog Ventures in St. Louis, serves on the Chlorogen board of directors.

Chlorogen has expressed a commercially important protein in tobacco and shown that this method of production is far less expensive than practically any other method. The fact that the recombinant genes are expressed in chloroplast rather than the nucleus prevents the uncontrolled spread of the Genetically Modified Orgasm (GMO) by pollen. Chlorogen has negotiated important partnerships with companies needing low cost protein production without contamination from animal pathogens or unwanted proteins. Chlorogen is funded by a syndicate of four venture capital funds including Prolog Ventures (www.prologventures.com), Burrill and Co. (www.burillandco.com), Harris and Harris (www.hhgp.com), and Redmont Venture Partners (www.redmontvp.com) $5.5 million was invested in the first round.

---

MO-SCI Corporation (Rolla, MO)

Dr. Delbert E. Day is Curators' Professor Emeritus of Ceramic Engineering at the University of Missouri-Rolla. While on the UMR faculty his teaching and research have dealt with the structure and properties of vitreous solids (glass). He conducted the first experiments of glass in micro gravity and will be conducting additional glass melting experiments on the International Space Station.

He is the co-investor of special purpose glass microspheres, TheraSphere™, which are now being used at 15 hosptitals in the USA to treat patients with liver cancer. Currently, he is developing biodegradable glass microspheres for treating rheumatoid arthritis, for long term drug delivery and for fillers in bioactive composites for bone repair.

Dr. Day founded MO-SCI Corporation in 1985 as a privately owned small business for the purpose of manufacturing TheraSpheres™. MO-SCI (www.mo-sci.com) has expanded into serving other markets that require high quality, specialty glass products and is the world's leading producer of specialty glass microspheres, fibers and frit. MO-SCI also provides engineering services to a wide range of companies that either manufacture glass products or use glass components in their products. Examples of products manufactured by MO-SCI are bioactive glasses used in dental restorations and for bone repair, specially designed glass microspheres used in blood typing and as taggants for security and product identification, microsphere spacers used in flat panel displays, automotive mirrors, adhesives, and glass filters for night vision devices.

---

Pet Healthcare International, Inc. (Columbia, MO)

Pet Healthcare International (PHI) (www.neutersol.com), was formed in 1990 for the purpose of raising capital for securing FDA approval for technology developed by Dr. Mostafa Fahim, a deceased faculty member of the University of Missouri-Columbia (MU) School of Medicine. Neutersol, an injectable compound for neutering male puppies, was the first product approved. The company laboratory is on the MU campus. The laboratory is supported with funding from PHI under an agreement with MU.

The investor shareholders of PHI are mostly central Missouri residents. Since securing approval from the FDA last year, PHI has entered into contracts with Meridan Medical in St. Louis, MO for production and with Addison Biological Laboratories in Fayette, MO for marketing. PHI is currently working on research and development to obtain approval for Neutersol in additional companion, farm and zoo animal species. PHI is also marketing over-the-counter human mouthwash and skin creams in China through a joint venture between PHI and Xi'an Medical University in Xi'an China.